Survival after radiation therapy for high-grade glioma.

Autor: Marra JS; Department of Radiation Oncology, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.; Department of Radiation Oncology, Hospital Regional do Cancer de Passos, Passos, MG, Brazil., Mendes GP; Department of Radiation Oncology, Centro de Radioterapia de São Carlos, São Carlos, SP, Brazil.; Department of Radiation Oncology, Serviço de Radioterapia da Santa Casa de Araraquara, Araraquara, SP, Brazil., Yoshinari GH Jr; Department of Radiation Oncology, Hospital Márcio Cunha, Fundação São Francisco Xavier, Ipatinga, MG, Brazil., da Silva Guimarães F; Department of Radiation Oncology, Centro de Radioterapia de São Carlos, São Carlos, SP, Brazil.; Department of Radiation Oncology, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil., Mazin SC; Department of Gynaecology and Obstetrics, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto - SP, Brazil., de Oliveira HF; Department of Radiation Oncology, Hospital Márcio Cunha, Fundação São Francisco Xavier, Ipatinga, MG, Brazil.; Department of Gynaecology and Obstetrics, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto - SP, Brazil.; Department of Radiation Oncology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.; Department of Radiation Oncology, Centro de Tratamento em Radio-oncologia, Ribeirão Preto, SP, Brazil.
Jazyk: angličtina
Zdroj: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2019 Jan-Feb; Vol. 24 (1), pp. 35-40. Date of Electronic Publication: 2018 Oct 11.
DOI: 10.1016/j.rpor.2018.09.003
Abstrakt: Background: High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy.
Aim: To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy.
Materials and Methods: Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively.
Results: Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27-123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes.
Conclusions: Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate ( p  < 0.05). The estimated overall survival was 18 months (Kaplan-Meier estimator). Our results corroborated those reported in the literature.
Databáze: MEDLINE
Externí odkaz: